This site is intended for health professionals only

Noncardiac drug risk framework call

teaser

Recommendations for rethinking regulatory policies on the cardiovascular risk of noncardiac drugs have been developed by a group of scientists and regulators, according to an article in the European Heart Journal.

The suggestions were originally developed at a December 2005 meeting of cardiovascular clinical trialists, biostatisticians, FDA and EMEA regulators, representatives of the US National Institutes of Health (NIH), and drug-industry scientists. They outline strategies to enable reasonably certain exclusion of unacceptable risks.

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

The authors note that several non-cardiac drugs (eg rofecoxib) have recently ceased marketing due to cardiovascular risk. They state: “Pharmacological actions of a single drug can differ among functionally different organ systems; benefit for non-cardiovascular targets may be associated with cardiovascular adversity.

“However, cardiovascular testing is not a major focus of evaluation and development of non-cardiovascular drugs. Consequently, at approval, the relation between non-cardiovascular benefit and cardiovascular risk may not be adequately defined”.

European Heart Journal, published online ahead of print 5/7/2007

 






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x